Lumos Pharma, Inc.

Lumos ended Q2 2024 with cash, cash equivalents and short-term investments of $16.8 million, versus $36 million at December 31, 2023. Research and development expense was $4.6 million, down $1.4 million year over year, and general and administrative expense was $3.7 million, down $0.5 million year over year. Net loss was $7.6 million, compared with a net loss of $8.9 million in the prior-year quarter. The company said the Phase 3 start has been extended into Q2 2025 and that this moves cash runway into Q1 next year; management also repeated that $85 million to $100 million would support operations through 2026.

Rick Hawkins framed the quarter as a de-risking moment for LUM-201, emphasizing the FDA’s support for a placebo-controlled registrational trial and saying that recognition of the drug’s unique mechanism strengthens the program. He said the company is pursuing both clinical progress and strategic alternatives, noting interest from investors and potential partners and describing the asset as potentially first-in-class in a $5 billion global growth hormone market. His tone was upbeat and confident, but he stressed prudent capital management and value maximization.

Lori Lawley focused on balance sheet management and spending discipline. She said cash and investments were $16.8 million at quarter-end, down from $36 million at year-end 2023, and that moving Phase 3 into Q2 2025 extends runway into Q1 next year. She reiterated prior guidance that $85 million to $100 million would support operations through 2026, and tied the capital plan to finalizing the Phase 3 design and launch preparations.

Analysts pressed on enrollment timing, possible interim looks, and how soon data might emerge; management said it expects 15 to 18 months to enroll about 150 patients and does not plan an interim peak, even blinded, to keep the study clean. Questions also focused on what could happen before the Phase 3 readout and whether ex-U.S. deals might help fund development; management said it is focused on PGHD first, but is actively evaluating strategic, regional, and global opportunities with Piper Sandler. The team also said the formulation change to mini-tablets in capsules was intended to improve dose precision and administration flexibility, and that a bridging PK study has already been completed.